DiagnoCure axes French subsidiary Samba
This article was originally published in Clinica
Executive Summary
Quebec-based cancer diagnostics company DiagnoCure has announced it will immediately stop funding its Samba Technologies subsidiary, based in Meylan, France. The digital imaging and IT business, which initially partnered with DiagnoCure for the automation of a bladder cancer immunoassay, "is outside of our molecular diagnostics focus", said DiagnoCure president and CEO John Schafer.